Research Perspective|Volume 3, Issue 12|pp 1154—1162

Recent progress in targeting cancer

Zoya N. Demidenko¹, James A. McCubrey²

¹Department of Cell Stress Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA
²Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA

Received: December 5, 2011Accepted: December 28, 2011Published: December 31, 2011

Copyright: © 2011 Demidenko et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

In recent years, numerous new targets have been identified and new experimental therapeutics have been developed. Importantly, existing non-cancer drugs found novel use in cancer therapy. And even more importantly, new original therapeutic strategies to increase potency, selectivity and decrease detrimental side effects have been evaluated. Here we review some recent advances in targeting cancer.